This inventor holds 2 USPTO granted patents. Top assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., Virginia Commonwealth University. Active years: 2010-2013.
Company Filing History:
1 out of 343 
1 out of 420 
Years Active: 2010-2013
Title: Daniele Simoni: Innovator in Cancer Therapeutics
Introduction
Daniele Simoni is a notable inventor based in Ferrara, Italy. He has made significant contributions to the field of cancer therapeutics, holding 2 patents that focus on innovative compounds with antitumoural activities. His work aims to address critical challenges in cancer treatment and improve patient outcomes.
Latest Patents
One of his latest patents is titled "Aryl isoxazole compounds with antitumoural activities." This invention relates to formula I compounds that exhibit antitumoural activities by targeting the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The patent includes the use of these compounds in medicine, particularly concerning cancer and other diseases responsive to Hsp90 inhibition, along with pharmaceutical compositions containing such compounds.
Another significant patent by Simoni is "Stilbene derivatives as new cancer therapeutic agents." This invention highlights the effectiveness of stilbene derivatives in killing and suppressing the growth of various cancer cells. These compounds have shown promise in suppressing tumor growth in vivo and may be utilized in treating diseases characterized by cell hyperproliferation, including human malignancies and non-malignant diseases like liver cirrhosis. Notably, stilbenes can disrupt abnormal vessels in tumors, achieving a vascular disrupting effect to further suppress tumor growth. Water-soluble pro-drug forms of stilbene derivatives are particularly advantageous in this context.
Career Highlights
Throughout his career, Daniele Simoni has worked with esteemed institutions such as Virginia Commonwealth University and Sigma-Tau Industrie Farmaceutiche Riunite S.p.a. His research and innovations have contributed to advancing cancer treatment methodologies.
Collaborations
Simoni has collaborated with notable colleagues, including Ruey-min Lee and Giuseppe Giannini. These partnerships have fostered a collaborative environment that enhances the development of innovative cancer therapies.
Conclusion
Daniele Simoni's work in developing novel cancer therapeutic agents showcases his commitment to improving treatment options for patients. His patents reflect a deep understanding of the complexities of cancer biology and the potential for innovative solutions in medicine.